Calcitonin gene-related peptide (CGRP) antagonist antibodies
AssigneeREMD Biotherapeutics, Inc.
InventorsFrank J Calzone, John Zhang
Life of this patent
Estimating the term…
Abstract
This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Calcitonin Gene Related Peptide (CGRP). These anti-CGRP antibodies, or antigen-binding fragments thereof, have a high affinity for CGRP, function to inhibit CGRP, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., a human) and can be used to treat CGRP-associated disorders, while avoiding the adverse side effects associated with the current CGRP antagonist therapies.
Claims16
An isolated antibody or antigen-binding fragment thereof, which specifically binds calcitonin gene-related peptide (CGRP) and comprises either:
- (a) the light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO:
- 9, SEQ ID NO:
- 12, and SEQ ID NO:
- 14 and the heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO:
- 2, SEQ ID NO:
- 3, and SEQ ID NO:
- 6;
- (b) the light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO:
- 10, SEQ ID NO:
- 13, and SEQ ID NO:
- 15 and the heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO:
- 2, SEQ ID NO:
- 4, and SEQ ID NO:
- 7;
- or (c) the light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO:
- 11, SEQ ID NO:
- 13, and SEQ ID NO:
- 16 and the heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO:
- 2, SEQ ID NO:
- 5, and SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.